Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III
Introduction: Intensive induction-consolidation chemotherapy achieves high rates of complete response (CR) in 90% of patients with newly diagnosed acute lymphoblastic leukemia (ALL). However, almost a half of the patients relapse and their outcome after frontline chemotherapy failure is essentially poor.
Methods: We retrospectively reviewed 463 patients with newly diagnosed Philadelphia-negative ALL from June 2002 to February 2015 at our institution. Overall survival was defined as the time interval from the date of relapse to the date of death. Kaplan-Meier method was used for survival analysis.
Results: Of the 463 patients, 155 (33%) relapsed. Data on salvage therapy and long term follow-up was available in 76 patients (17%). The median time to relapse was 15 months (range, 1-111 months). The median number of salvage regimens administered was 1 (range, 1-7). Overall, 76 patients received at least 1 salvage therapy. Thirty (39%) patients received at least 2 salvage regimens and 18 (24%) received 3 or more salvage regimens. Baseline patient characteristics are summarized in the table 1. Median follow-up after frontline therapy failure was 16 months. The median survival after relapse was 8.3 months with the 1- year and 2-year survival rates being 46 % and 28% respectively.
Salvage 1 included augmented HCVAD [n=13; 7/13 responses (6 CR, 1 CRp) for a median of 6 months], asparaginase based therapies [n=6; 2/6 response (2 CR) for a median of 2 months], monoclonal antibodies (MAB), blinatumomab, inotuzumab ozogamicin [n=19; 11/19 responses (6 CR, 5 CRp) for a median of 7 months], HCVAD + anti-CD20 antibody [n=11; 8/11 responses (5 CR, 3 CRp) for a median of 6 months], Miscellaneous [n=22; 2/22 responses (2 CR)] and HCVAD [n=5; 1/5 response (1 CR) for 1 month]. The overall response rate to Salvage 1 was 41% (22 CR, 9 CRp) for a median of 6 months. Nineteen (25%) patients received subsequent allogeneic stem cell transplantation (ASCT); 11 of them are alive with a median of 2 years with 7 of them in CR.
Thirty patients received a second salvage regimen; the most commonly used one consisted of MAB (blinatumomab; inotuzumomab ozogamicin) [n=8; 4/8 responses (2 CR, 2 CRp) for a median of 2.5 months]. The overall response rate to salvage 2 was 30% (6 CR, 3 CRp) for a median of 3 months.
At the last follow-up, overall 23 patients remained alive, 9 of them in CR.
Conclusions: Outcome of patients with Philadelphia-negative ALL post frontline therapies failure is poor with a median survival of only 8.3 months. Though some salvage therapies can induce remissions, response durations are limited. Stem cell transplant after remission offers a potential of long term cure. These patients should be referred to clinical trials.
Table 1. Baseline characteristics and outcome of adults with relapsed B cell ALL (Ph -)
who received salvage chemotherapy :
| N (%)/ Median [range] N= 76
|
Age (years)
| 36 (18-86)
|
Age ³ 60
| 15 (20)
|
Male
| 46 (61)
|
PS 2-3
| 9 (12)
|
WBC at diagnosis (x 109/L)
| 7.2 [1-602]
|
CD20 positivity at diagnosis
| 24 (32)
|
Cytogenetic Abnormality | |
Diploid
| 22 (29)
|
Hypodiploid
| 8 (11)
|
Hyperdiploid
| 12 (16)
|
t(4;11)
| 5 (7)
|
Miscellaneous
| 28 (37)
|
Type of Induction chemotherapy, No. (%)
| |
Augmented BFM | 28 (37)
|
HCVAD | 21 (28)
|
HCVAD + anti-CD20 antibody | 27 (35)
|
Overall response to frontline therapy
| |
CR | 73 (96)
|
CR without platelet count recovery | 2 (3)
|
Partial response | 1 (1)
|
Median response duration, (month)
| 15[1-63]
|
Response duration <12 months
| 35 (46)
|
Complete response to salvage chemotherapy
| |
S1 | 31/76 (41)
|
S2 | 9/30 (30)
|
S3 or more | 3/18 (17) |
Allogeneic stem cell transplant
| 19 (25)
|
Figure 1. Overall survival
Disclosures: Cortes: Novartis: Consultancy , Research Funding ; Pfizer: Consultancy , Research Funding ; BerGenBio AS: Research Funding ; BMS: Consultancy , Research Funding ; Teva: Research Funding ; Ariad: Consultancy , Research Funding ; Astellas: Consultancy , Research Funding ; Ambit: Consultancy , Research Funding ; Arog: Research Funding ; Celator: Research Funding ; Jenssen: Consultancy . Daver: ImmunoGen: Other: clinical trial , Research Funding . Konopleva: Novartis: Research Funding ; AbbVie: Research Funding ; Stemline: Research Funding ; Calithera: Research Funding ; Threshold: Research Funding .
See more of: Acute Lymphoblastic Leukemia: Clinical Studies
See more of: Oral and Poster Abstracts
*signifies non-member of ASH